Literature DB >> 27821503

Classification systems for chronic graft-versus-host disease.

Stephanie J Lee1.   

Abstract

Chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Clinically, chronic GVHD is a pleiotropic, multiorgan syndrome involving tissue inflammation and fibrosis that often results in permanent organ dysfunction. Chronic GVHD is fundamentally caused by replacement of the host's immune system with donor cells, although the heterogeneity of clinical manifestations suggests that patient, donor, and transplant factors modulate the phenotype. The diagnosis of chronic GVHD and determination of treatment response largely rely on clinical examination and patient interview. The 2005 and 2014 National Institutes of Health Consensus Development Projects on Criteria for Clinical Trials in Chronic GVHD standardized the terminology around chronic GVHD classification systems to ensure that a common language and procedures are being used in clinical research. This review provides a summary of these recommendations and illustrates how they are being used in clinical research and the potential for their use in clinical care.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 27821503      PMCID: PMC5216262          DOI: 10.1182/blood-2016-07-686642

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  92 in total

1.  Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Can-Lan Sun; Liton Francisco; Toana Kawashima; Wendy Leisenring; Leslie L Robison; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

2.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Authors:  David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers
Journal:  Blood       Date:  2012-07-06       Impact factor: 22.113

3.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

4.  2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

Authors:  Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-05       Impact factor: 5.742

5.  Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Philipp Yorck Herzberg; Pia Heussner; Friederike H A Mumm; Melanie Horak; Inken Hilgendorf; Stephanie von Harsdorf; Philipp Hemmati; Kathrin Rieger; Hildegard Greinix; Mathias Freund; Stephanie J Lee; Ernst Holler; Daniel Wolff
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-09       Impact factor: 5.742

6.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Brenda Kurland; Xiaoyu Chai; Navneet Majhail; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; David Jacobsohn; Jeanne Palmer; Sally Arai; Madan Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

Review 7.  Have we made progress in the management of chronic graft-vs-host disease?

Authors:  Stephanie J Lee
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-02       Impact factor: 3.020

8.  Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Authors:  Kristin Baird; Leora E Comis; Galen O Joe; Seth M Steinberg; Fran T Hakim; Jeremy J Rose; Sandra A Mitchell; Steven Z Pavletic; William D Figg; Lawrence Yao; Kathleen C Flanders; Naoko Takebe; Stefanie Sarantopoulos; Susan Booher; Edward W Cowen
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

9.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

10.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Authors:  B-S Cho; C-K Min; K-S Eom; Y-J Kim; H-J Kim; S Lee; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

View more
  74 in total

1.  The benefit of exercise in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Shinichiro Morishita; Atsuhiro Tsubaki; Kazuki Hotta; Jack B Fu; Shigeo Fuji
Journal:  J Int Soc Phys Rehabil Med       Date:  2019-05-22

2.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

3.  Mouse Models of Skin Fibrosis.

Authors:  Aleix Rius Rigau; Markus Luber; Jörg H W Distler
Journal:  Methods Mol Biol       Date:  2021

4.  Cytokines in umbilical cord blood-derived cellular product: a mechanistic insight into bone repair.

Authors:  Mukta S Sane; Neha Misra; Omid Mohammad Mousa; Steve Czop; Huiyuan Tang; Larry T Khoo; Christopher D Jones; Soumyajit Banerjee Mustafi
Journal:  Regen Med       Date:  2018-10-22       Impact factor: 3.806

5.  BCL6 inhibition: a chronic GVHD twofer.

Authors:  Paola Vinci; Alan M Hanash
Journal:  Blood       Date:  2019-01-03       Impact factor: 22.113

6.  Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.

Authors:  Sherif S Farag; Mohammad Abu Zaid; Jennifer E Schwartz; Teresa C Thakrar; Ann J Blakley; Rafat Abonour; Michael J Robertson; Hal E Broxmeyer; Shuhong Zhang
Journal:  N Engl J Med       Date:  2021-01-07       Impact factor: 91.245

7.  A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Authors:  T H A Tvedt; R Hovland; G Tsykunova; A B Ahmed; T Gedde-Dahl; Ø Bruserud
Journal:  Clin Exp Immunol       Date:  2018-04-01       Impact factor: 4.330

Review 8.  B cells in chronic graft-versus-host disease.

Authors:  William McManigle; Ayman Youssef; Stefanie Sarantopoulos
Journal:  Hum Immunol       Date:  2019-03-05       Impact factor: 2.850

9.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

10.  Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.

Authors:  Kristina Maas-Bauer; Chrissoula Kiote-Schmidt; Hartmut Bertz; Petya Apostolova; Ralph Wäsch; Gabriele Ihorst; Jürgen Finke; Robert Zeiser
Journal:  Bone Marrow Transplant       Date:  2020-11-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.